Literature review on the treatment progress of HER2-positive advanced breast cancer

Breast cancer is the most common malignant tumor among women in China.

The treatment of patients with HER2-positive advanced breast cancer is also a major topic in clinical work.

The discovery of the HER2 gene

HER/neu was first discovered by Genetech scientist Axel Ullrich in 1984, and was featured on the cover of NATURE magazine

2.

Usually, the key clinical studies for new drug listings are late-stage first-line treatment studies, which can obtain results faster and more easily obtain good curative effect results

Follow-up first-line therapy also includes dual-target therapy.

3.

The VEMILIA study is a pivotal phase III study of T-DM1 in the second-line treatment of HER2-positive advanced breast cancer conducted by Verma et al.

Professor Xu conducted a multi-center, open-label, randomized, controlled, phase 3 trial (NCT03080805), the PHOEBE study, which laid the foundation for the second-line treatment regimen in China

The newly published open-label, multicenter DESTINY-Breast03 study in 2022, which is the first randomized phase III study of T-DXd, includes patients with unresectable or metastatic HER2-positive breast cancer, advanced stage, previously received For trastuzumab and taxane therapy and for clinically stable treated brain metastases, the treatment group was given T-DXd 5.

Fourth, after-line treatment

After first-line and second-line therapy, the latter-line therapy has also made great progress

Therefore, the advent of new targeted therapy drugs has promoted the progress of the treatment of HER2-positive MBC, and related research results have also been published in many important journals